Asia FX rises; US-Japan trade deal boosts yen, won to 2-week highs
RAHWAY, N.J. - Pharmaceutical giant Merck (NYSE:MRK) announced Tuesday that its Board of Directors has declared a quarterly dividend of $0.81 per share of common stock for the fourth quarter of 2025. The company has maintained dividend payments for 55 consecutive years and has raised its dividend for 14 straight years, with the current yield standing at 4.09%.
The dividend will be paid on October 7, 2025, to shareholders of record at the close of business on September 15, 2025, according to a company press release.
Merck, which operates as MSD outside the United States and Canada, is a research-focused biopharmaceutical company that develops medicines and vaccines. The company has been in operation for more than 130 years.
The quarterly dividend announcement comes as part of the company’s regular financial operations. Merck, like many established pharmaceutical companies, provides regular dividend payments to its shareholders.
The company’s stock is traded on the New York Stock Exchange under the ticker symbol MRK.
In other recent news, Merck has announced the initiation of its EXPrESSIVE Phase 3 clinical trials for MK-8527, a once-monthly oral medication aimed at HIV prevention. The trials will take place across 16 countries and focus on individuals with a higher likelihood of HIV-1 exposure, as well as women and adolescent girls in sub-Saharan Africa. Additionally, the U.S. Food and Drug Administration has accepted Merck’s New Drug Application for a two-drug HIV treatment, setting a target action date of April 28, 2026. In corporate developments, Merck has confirmed a $10 billion acquisition of London-based Verona Pharma, a move that has received a reiterated Buy rating from UBS with a $105.00 price target. Conversely, Cantor Fitzgerald maintained a Neutral rating on Merck with an $83.00 price target after evaluating the financial implications of the Verona deal. Merck has also committed to using Veeva Systems’ Vault CRM for its upcoming product launches, marking an expansion of their strategic partnership. These developments highlight Merck’s ongoing efforts in both pharmaceutical innovation and strategic corporate activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.